他汀类药物治疗与类鼻疽患者后续临床病程的关系。

IF 2.5 4区 医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Journal of Tropical Medicine Pub Date : 2025-05-25 eCollection Date: 2025-01-01 DOI:10.1155/jotm/8838580
Laura Prideaux, Hayley Stratton, Meg Sandeman, Simon Smith, Josh Hanson
{"title":"他汀类药物治疗与类鼻疽患者后续临床病程的关系。","authors":"Laura Prideaux, Hayley Stratton, Meg Sandeman, Simon Smith, Josh Hanson","doi":"10.1155/jotm/8838580","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Even in well-resourced settings, the case-fatality rate of melioidosis approaches 10%. This has prompted an interest in identifying adjunctive therapies that might improve survival. A prospective, multicentre study in Thailand suggested that statin therapy may reduce the incidence of pneumonia in patients with melioidosis; however, the impact of statins on the clinical course of patients with the infection is incompletely defined. <b>Materials and Methods:</b> We examined all cases of culture-confirmed melioidosis in Far North Queensland, tropical Australia, since October 2016 to determine if statin therapy influenced the clinical phenotype of melioidosis and the patients' clinical course. <b>Results:</b> Of 321 individuals with culture-confirmed melioidosis, 100 (31%) were prescribed a statin at the time of their diagnosis. There was no difference in the clinical phenotype of patients who were- and were not-taking statin therapy. Pulmonary involvement, specifically, was no less common in patients taking a statin (79/100 [79%] versus 175/221 [79%], <i>p</i> = 0.97). A smaller proportion of patients taking statin therapy died before hospital discharge, but this difference did not reach statistical significance (5/100 [5%] versus 26/221 [12%], <i>p</i> = 0.07). This finding was at least partially explained by the fact that fewer patients with an active malignancy were taking a statin (7/37 [19%] versus 93/284 [33%] patients without a malignancy, <i>p</i> = 0.09) and that, in multivariable analysis, patients with malignancy were more likely to die before hospital discharge (odds ratio [95% confidence interval]: 4.73 [1.62-13.87], <i>p</i> = 0.005). Among 290 individuals surviving to hospital discharge, there was no difference in 12-month mortality between those that were-and were not-prescribed a statin at presentation (11/95 [12%] versus 23/195 [12%], <i>p</i> = 0.96). <b>Conclusion:</b> Statin therapy does not appear to have any significant influence on the clinical phenotype of patients with melioidosis. There is also no appreciable impact of statin therapy on patients with melioidosis' short-term or 12-month survival.</p>","PeriodicalId":17527,"journal":{"name":"Journal of Tropical Medicine","volume":"2025 ","pages":"8838580"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12127124/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Association Between Statin Therapy and the Subsequent Clinical Course of Patients With Melioidosis.\",\"authors\":\"Laura Prideaux, Hayley Stratton, Meg Sandeman, Simon Smith, Josh Hanson\",\"doi\":\"10.1155/jotm/8838580\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Even in well-resourced settings, the case-fatality rate of melioidosis approaches 10%. This has prompted an interest in identifying adjunctive therapies that might improve survival. A prospective, multicentre study in Thailand suggested that statin therapy may reduce the incidence of pneumonia in patients with melioidosis; however, the impact of statins on the clinical course of patients with the infection is incompletely defined. <b>Materials and Methods:</b> We examined all cases of culture-confirmed melioidosis in Far North Queensland, tropical Australia, since October 2016 to determine if statin therapy influenced the clinical phenotype of melioidosis and the patients' clinical course. <b>Results:</b> Of 321 individuals with culture-confirmed melioidosis, 100 (31%) were prescribed a statin at the time of their diagnosis. There was no difference in the clinical phenotype of patients who were- and were not-taking statin therapy. Pulmonary involvement, specifically, was no less common in patients taking a statin (79/100 [79%] versus 175/221 [79%], <i>p</i> = 0.97). A smaller proportion of patients taking statin therapy died before hospital discharge, but this difference did not reach statistical significance (5/100 [5%] versus 26/221 [12%], <i>p</i> = 0.07). This finding was at least partially explained by the fact that fewer patients with an active malignancy were taking a statin (7/37 [19%] versus 93/284 [33%] patients without a malignancy, <i>p</i> = 0.09) and that, in multivariable analysis, patients with malignancy were more likely to die before hospital discharge (odds ratio [95% confidence interval]: 4.73 [1.62-13.87], <i>p</i> = 0.005). Among 290 individuals surviving to hospital discharge, there was no difference in 12-month mortality between those that were-and were not-prescribed a statin at presentation (11/95 [12%] versus 23/195 [12%], <i>p</i> = 0.96). <b>Conclusion:</b> Statin therapy does not appear to have any significant influence on the clinical phenotype of patients with melioidosis. There is also no appreciable impact of statin therapy on patients with melioidosis' short-term or 12-month survival.</p>\",\"PeriodicalId\":17527,\"journal\":{\"name\":\"Journal of Tropical Medicine\",\"volume\":\"2025 \",\"pages\":\"8838580\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-05-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12127124/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Tropical Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/jotm/8838580\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Tropical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/jotm/8838580","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

背景:即使在资源充足的环境中,类鼻疽的病死率也接近10%。这引起了人们对确定可能提高生存率的辅助疗法的兴趣。泰国的一项前瞻性多中心研究表明,他汀类药物治疗可降低类鼻疽患者肺炎的发病率;然而,他汀类药物对感染患者临床病程的影响尚不完全明确。材料和方法:自2016年10月以来,我们检查了澳大利亚热带昆士兰州远北地区所有经培养确诊的类鼻疽病例,以确定他汀类药物治疗是否影响类鼻疽的临床表型和患者的临床病程。结果:在321例经培养证实的类鼻疽患者中,100例(31%)在诊断时服用了他汀类药物。接受他汀类药物治疗和未接受他汀类药物治疗的患者的临床表型没有差异。特别是肺部受累在服用他汀类药物的患者中并不少见(79/100 [79%]vs 175/221 [79%], p = 0.97)。接受他汀类药物治疗的患者出院前死亡比例较小,但差异无统计学意义(5/100 [5%]vs 26/221 [12%], p = 0.07)。这一发现至少可以部分解释如下事实,即较少的活动性恶性肿瘤患者服用他汀类药物(7/37[19%]对93/284[33%]无恶性肿瘤,p = 0.09),并且在多变量分析中,恶性肿瘤患者更有可能在出院前死亡(优势比[95%置信区间]:4.73 [1.62-13.87],p = 0.005)。在存活至出院的290例患者中,就诊时服用和未服用他汀类药物的患者12个月死亡率无差异(11/95[12%]对23/195 [12%],p = 0.96)。结论:他汀类药物治疗似乎对类鼻炎患者的临床表型没有显著影响。他汀类药物治疗对类鼻炎患者的短期或12个月生存率也没有明显影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Association Between Statin Therapy and the Subsequent Clinical Course of Patients With Melioidosis.

Background: Even in well-resourced settings, the case-fatality rate of melioidosis approaches 10%. This has prompted an interest in identifying adjunctive therapies that might improve survival. A prospective, multicentre study in Thailand suggested that statin therapy may reduce the incidence of pneumonia in patients with melioidosis; however, the impact of statins on the clinical course of patients with the infection is incompletely defined. Materials and Methods: We examined all cases of culture-confirmed melioidosis in Far North Queensland, tropical Australia, since October 2016 to determine if statin therapy influenced the clinical phenotype of melioidosis and the patients' clinical course. Results: Of 321 individuals with culture-confirmed melioidosis, 100 (31%) were prescribed a statin at the time of their diagnosis. There was no difference in the clinical phenotype of patients who were- and were not-taking statin therapy. Pulmonary involvement, specifically, was no less common in patients taking a statin (79/100 [79%] versus 175/221 [79%], p = 0.97). A smaller proportion of patients taking statin therapy died before hospital discharge, but this difference did not reach statistical significance (5/100 [5%] versus 26/221 [12%], p = 0.07). This finding was at least partially explained by the fact that fewer patients with an active malignancy were taking a statin (7/37 [19%] versus 93/284 [33%] patients without a malignancy, p = 0.09) and that, in multivariable analysis, patients with malignancy were more likely to die before hospital discharge (odds ratio [95% confidence interval]: 4.73 [1.62-13.87], p = 0.005). Among 290 individuals surviving to hospital discharge, there was no difference in 12-month mortality between those that were-and were not-prescribed a statin at presentation (11/95 [12%] versus 23/195 [12%], p = 0.96). Conclusion: Statin therapy does not appear to have any significant influence on the clinical phenotype of patients with melioidosis. There is also no appreciable impact of statin therapy on patients with melioidosis' short-term or 12-month survival.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Tropical Medicine
Journal of Tropical Medicine Immunology and Microbiology-Parasitology
CiteScore
3.90
自引率
4.50%
发文量
0
审稿时长
14 weeks
期刊介绍: Journal of Tropical Medicine is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies on all aspects of tropical diseases. Articles on the pathology, diagnosis, and treatment of tropical diseases, parasites and their hosts, epidemiology, and public health issues will be considered. Journal of Tropical Medicine aims to facilitate the communication of advances addressing global health and mortality relating to tropical diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信